Fig. 1 · Structure

Documents & Downloads

Go 6976

Cat. No. A12419 CAS 136194-77-9

PKC inhibitor

Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
JAK2 N/A
FLT3
PKCα 2.3 nM
PKCβ1 6.2 nM
PKC (Rat brain) 7.9 nM

Cellular Effect

Cell Line Activity Value Description Reference
Vero CC50 6 μM Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured on day 5 post dose by MTS/PMS based microscopic analysis [PMID: 28689975]

Go 6976 Research Summary

This section summarizes 2 in vitro studies of Go 6976 from 2 published references. In vitro models include LRRK2 G2019S astrocytes; HLMVEC cells.

Go 6976 In Vitro Studies

Go 6976 (10 µM) did not prevent Glt-1 clustering in LRRK2 G2019S astrocytes compared with LRRK2 G2019S controls. In HLMVEC cells stimulated with listeriolysin or pneumolysin, pretreatment with Go 6976 (1 µM) significantly decreased toxin-induced PKC-substrate phosphorylation compared with cells without the inhibitor. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Go 6976 did not prevent Glt-1 clustering

Cell-based study · LRRK2 G2019S astrocytes [1]

Go 6976 (10 µM) did not prevent Glt-1 clustering in LRRK2 G2019S astrocytes in the comparison of LRRK2 G2019S versus LRRK2 G2019S + Go 6976.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of Glt-1-positive clusters per cellReported result PKC inhibition using Go 6976 (10 µM) did not prevent Glt-1 clustering in LRRK2 G2019S astrocytes (LRRK2 G2019S vs LRRK2 G2019S + Go 6976, p = 0.1645).[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Co-treatment
Other interventions in this design: Flag-Glt-1. Compound effect isolated by the comparison: LRRK2 G2019S vs LRRK2 G2019S + Go 6976.
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Go 6976

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Pharmacological treatments (S145); Results > Glt-1 displays an altered localization in LRRK2 G2019S astrocytes (S238); Fig. 4 legend (S309, S311)

number of Glt-1-positive clusters per cell: number of Glt-1-positive clusters per cell; comparator: LRRK2 G2019S — Materials and methods > Pharmacological treatments (S145); Results > Glt-1 displays an altered localization in LRRK2 G2019S astrocytes (S238); Fig. 4 legend (S311)

PKC-Substrate Phosphorylation in Toxin-Stimulated HLMVEC Cells

Cell-based study · HLMVEC cells [2]

HLMVEC cells were pretreated with or without Go 6976 (1 µM) before stimulation with listeriolysin or pneumolysin. Both toxins increased PKC-substrate phosphorylation, which was significantly decreased by Go 6976.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of PKC-substratesReported result HLMVEC cells were pretreated with or without the PKCα inhibitor (Go6976, 1 µM) and stimulated with listeriolysin (LLO, 60 ng/ml) or pneumolysin (PLY, 30 ng/ml) for 30 min. Both LLO and PLY increased the phosphorylation of PKC-substrates and this was significantly decreased by the PKC inhibitor Go6976.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
stimulated with listeriolysin (LLO, 60 ng/ml) or pneumolysin (PLY, 30 ng/ml) for 30 min.
Method
pretreated
Co-treatment
Other interventions in this design: listeriolysin 60 ng/ml. Compound effect isolated by the comparison: pretreated with or without the PKCα inhibitor (Go6976, 1 µM).
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Go 6976

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > G+-toxins stimulate PKCα and eNOS T495 phosphorylation (S42); Figure 3 legend (S75)

phosphorylation of PKC-substrates: phosphorylation of PKC-substrates; comparator: without the PKCα inhibitor (Go6976, 1 µM) — Results > G+-toxins stimulate PKCα and eNOS T495 phosphorylation (S42); Figure 3 legend (S75)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 136194-77-9
Applications PKC inhibitor
Formula C24H18N4O
Molecular Weight 378.43
SMILES
CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 18 mg/mL (47.69 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
0.5% CMC Na+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Go 6976 Research References

  1. [1] Iovino L, Giusti V, Pischedda F, et al. Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease. Acta Neuropathol (2022). PMID: 35596783 DOI: 10.1007/s00401-022-02437-0 Source material
  2. [2] Chen F, Kumar S, Yu Y, et al. PKC-dependent phosphorylation of eNOS at T495 regulates eNOS coupling and endothelial barrier function in response to G+ -toxins. PLoS One (2014). PMID: 25020117 DOI: 10.1371/journal.pone.0099823 Source material

Added to your cart

View Cart Checkout
Loading...